Health disparities in COVID-19: immune and vascular changes are linked to disease severity and persist in a high-risk population in Riverside County, California

[1]  V. Herrera,et al.  Circulating neutrophil extracellular trap (NET)-forming ‘rogue’ neutrophil subset, immunotype [DEspR + CD11b +], mediate multi-organ failure in COVID-19—an observational study , 2023, Translational Medicine Communications.

[2]  R. Root-Bernstein.  From Co-Infections to Autoimmune Disease via Hyperactivated Innate Immunity: COVID-19 Autoimmune Coagulopathies, Autoimmune Myocarditis and Multisystem Inflammatory Syndrome in Children , 2023, International journal of molecular sciences.

[3]  M. Jacobs,et al.  Racial, ethnic, and sex disparities in the incidence and cognitive symptomology of long COVID-19 , 2023, Journal of the National Medical Association.

[4]  E. Topol,et al.  Long COVID: major findings, mechanisms and recommendations , 2023, Nature Reviews Microbiology.

[5]  Victor J. Avila-Quintero,et al.  Association Between Patient Race and Ethnicity and Outcomes With COVID-19: A Retrospective Analysis From a Large Mid-Atlantic Health System , 2023, Journal of intensive care medicine.

[6]  H. Niessen,et al.  Atrial inflammation and microvascular thrombogenicity are increased in deceased COVID-19 patients , 2023, Cardiovascular Pathology.

[7]  T. Aspelund,et al.  Correlates of Coronavirus Disease 2019 Inpatient Mortality at a Southern California Community Hospital With a Predominantly Hispanic/Latino Adult Population , 2023, Open forum infectious diseases.

[8]  C. Fisher,et al.  Psychological Well-Being and Substance Use During the COVID-19 Pandemic: Ethnic/Racial Identity, Discrimination, and Vigilance , 2022, Journal of racial and ethnic health disparities.

[9]  I. Kalomenidis,et al.  Kinetics of Immune Subsets in COVID-19 Patients Treated with Corticosteroids , 2022, Viruses.

[10]  M. Sato,et al.  Severe COVID‐19 patients show a dysregulation of the NLRP3 inflammasome in circulating neutrophils , 2022, Scandinavian journal of immunology.

[11]  L. Wooldridge,et al.  Hyperactive immature state and differential CXCR2 expression of neutrophils in severe COVID-19 , 2022, Life Science Alliance.

[12]  M. Shkurnikov,et al.  Association of HLA Class I Genotype with Mortality in Patients with Diabetes Mellitus and COVID-19 , 2022, Doklady Biochemistry and Biophysics.

[13]  H. Hamadi,et al.  COVID-19 Deaths and the Impact of Health Disparities, Hospital Characteristics, Community, Social Distancing, and Health System Competition. , 2022, Population health management.

[14]  Rana Chakraborty,et al.  The Elephant in the Waiting Room: An Urgent Call for Papers to Address the Public Health Crisis of Long COVID , 2022, Clinical nursing research.

[15]  Young Hee Jung,et al.  Preliminary Guidelines for the Clinical Evaluation and Management of Long COVID , 2022, Infection & chemotherapy.

[16]  A. Godzik,et al.  Resistin Concentration in Early Sepsis and All-Cause Mortality at a Safety-Net Hospital in Riverside County , 2022, Journal of inflammation research.

[17]  R. Rabuñal Rey,et al.  Assessment of Post-COVID Symptoms Using the C19-YRS Tool in a Cohort of Patients from the First Pandemic Wave in Northwestern Spain. , 2022, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.

[18]  L. Cardell,et al.  A prolonged innate systemic immune response in COVID-19 , 2022, Scientific Reports.

[19]  W. Wierzba,et al.  Remodeling of T Cell Dynamics During Long COVID Is Dependent on Severity of SARS-CoV-2 Infection , 2022, Frontiers in Immunology.

[20]  S. Straudi,et al.  Construct Validity and Responsiveness of the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS) in a Cohort of Italian Hospitalized COVID-19 Patients , 2022, International journal of environmental research and public health.

[21]  Y. Tizabi,et al.  COVID-19-Associated Coagulopathy: Role of Vitamins D and K. , 2022, Current Pharmaceutical Biotechnology.

[22]  T. Mak,et al.  Immune response in COVID-19: what is next? , 2022, Cell Death & Differentiation.

[23]  A. Iwasaki,et al.  Unexplained post-acute infection syndromes , 2022, Nature Medicine.

[24]  Hui Li,et al.  Identification of Neutrophil-Related Factor LCN2 for Predicting Severity of Patients With Influenza A Virus and SARS-CoV-2 Infection , 2022, Frontiers in Microbiology.

[25]  S. Cavallero,et al.  An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages , 2022, Theranostics.

[26]  A. Brazma,et al.  Single-Cell Analysis Reveals the Immune Characteristics of Myeloid Cells and Memory T Cells in Recovered COVID-19 Patients With Different Severities , 2022, Frontiers in Immunology.

[27]  M. Sivan,et al.  Post‐COVID syndrome symptoms, functional disability, and clinical severity phenotypes in hospitalized and nonhospitalized individuals: A cross‐sectional evaluation from a community COVID rehabilitation service , 2021, Journal of medical virology.

[28]  Diego C. B. Mariano,et al.  VTR: A Web Tool for Identifying Analogous Contacts on Protein Structures and Their Complexes , 2021, Frontiers in Bioinformatics.

[29]  H. Li,et al.  Immune signatures underlying post-acute COVID-19 lung sequelae , 2021, Science Immunology.

[30]  Matthew S. Miller,et al.  Lasting Changes to Circulating Leukocytes in People with Mild SARS-CoV-2 Infections , 2021, medRxiv.

[31]  S. Barry,et al.  Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection , 2021, BMC Medicine.

[32]  Konrad U. Förstner,et al.  6th European Congress of Immunology, 1-4 September 2021, Virtual meeting. , 2021, European journal of immunology.

[33]  N. Preston,et al.  The COVID‐19 Yorkshire Rehabilitation Scale (C19‐YRS): Application and psychometric analysis in a post‐COVID‐19 syndrome cohort , 2021, medRxiv.

[34]  S. Boyd,et al.  Antibody and B cell responses to SARS-CoV-2 infection and vaccination , 2021, Cell Host & Microbe.

[35]  S. Kent,et al.  Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection , 2021, medRxiv.

[36]  J. Lord,et al.  Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets , 2021, Frontiers in Immunology.

[37]  J. Goeman,et al.  Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2 specific CD8 T cell responses following COVID-19 , 2021, medRxiv.

[38]  M. Sivan,et al.  The self-report version and digital format of the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS) for Long Covid or Post-COVID syndrome assessment and monitoring , 2021 .

[39]  M. Katz,et al.  Racial and Ethnic Health Disparities Related to COVID-19. , 2021, JAMA.

[40]  R. Jafari,et al.  Monocytes and macrophages in COVID-19: Friends and foes , 2021, Life Sciences.

[41]  M. V. van Zelm,et al.  Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence , 2020, Science Immunology.

[42]  Hong-juan Liu,et al.  Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes , 2020, Journal of leukocyte biology.

[43]  N. Babel,et al.  Impaired Cytotoxic CD8+ T Cell Response in Elderly COVID-19 Patients , 2020, mBio.

[44]  A. Nicholson,et al.  Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study , 2020, The Lancet Microbe.

[45]  Manoj Sivan,et al.  Postdischarge symptoms and rehabilitation needs in survivors of COVID‐19 infection: A cross‐sectional evaluation , 2020, Journal of medical virology.

[46]  P. Groeneveld,et al.  Health Disparities and the Coronavirus Disease 2019 (COVID-19) Pandemic in the USA , 2020, Journal of General Internal Medicine.

[47]  V. Fuster,et al.  Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19 , 2020, Journal of the American College of Cardiology.

[48]  R. Assaly,et al.  Elevated interleukin‐6 and severe COVID‐19: A meta‐analysis , 2020, Journal of medical virology.

[49]  W. Tang,et al.  Myeloperoxidase: a potential therapeutic target for coronary artery disease , 2020, Expert opinion on therapeutic targets.

[50]  M. Netea,et al.  Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure , 2020, Cell Host & Microbe.

[51]  Yutao Guo,et al.  COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up , 2020, Journal of the American College of Cardiology.

[52]  R. Trimble.  COVID-19 Dashboard , 2020 .

[53]  Qiurong Ruan,et al.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.

[54]  T. Davenport,et al.  The potential for artificial intelligence in healthcare , 2019, Future Healthcare Journal.

[55]  K. Borgwardt,et al.  Machine Learning in Medicine , 2015, Mach. Learn. under Resour. Constraints Vol. 3.

[56]  R. Foresti,et al.  Human Sickle Cell Blood Modulates Endothelial Heme Oxygenase Activity: Effects on Vascular Adhesion and Reactivity , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[57]  I. Tanganelli,et al.  Oxidative stress, erythrocyte ageing and plasma non-protein-bound iron in diabetic patients , 2008, Free radical research.

[58]  Shizuo Akira,et al.  Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron , 2004, Nature.

[59]  A. Asada,et al.  Elevated methemoglobin in patients with sepsis , 1998, Acta anaesthesiologica Scandinavica.

[60]  A. Dauod,et al.  Long COVID-19 prevalence among a sample of infected people in Erbil city. , 2022, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique.

[61]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..